From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.

MLA

Pirker, Robert, and Martin Filipits. “From Crizotinib to Lorlatinib: Continuous Improvement in Precision Treatment of ALK-Positive Non-Small Cell Lung Cancer.” ESMO Open, vol. 4, no. 5, Sept. 2019, p. e000548. EBSCOhost, https://doi.org/10.1136/esmoopen-2019-000548.

APA

Pirker, R., & Filipits, M. (2019). From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. ESMO Open, 4(5), e000548. https://doi.org/10.1136/esmoopen-2019-000548

Chicago

Pirker, Robert, and Martin Filipits. 2019. “From Crizotinib to Lorlatinib: Continuous Improvement in Precision Treatment of ALK-Positive Non-Small Cell Lung Cancer.” ESMO Open 4 (5): e000548. doi:10.1136/esmoopen-2019-000548.